Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters










Publication year range
2.
Br J Cancer ; 108(12): 2516-24, 2013 Jun 25.
Article in English | MEDLINE | ID: mdl-23652300

ABSTRACT

BACKGROUND: Glioma stem-like cell (GSC) properties are responsible for gliomagenesis and recurrence. GSCs are invasive but its mechanism remains to be elucidated. Here, we attempted to identify the molecules that promote invasion in GSCs. METHODS: Neurospheres and CD133⁺ cells were collected from glioblastoma (GBM) specimens and glioma cell lines by sphere-formation method and magnetic affinity cell sorting, respectively. Differential expression of gene candidates, its role in invasion and its signaling pathway were evaluated in glioma cell lines. RESULTS: Neurospheres from surgical specimens attached to fibronectin and laminin, the receptors of which belong to the integrin family. Integrin α3 was overexpressed in CD133⁺ cells compared with CD133⁻ cells in all the glioma cell lines (4 out of 4). Immunohistochemistry demonstrated the localisation of integrin α3 in GBM cells, including invading cells, and in the tumour cells around the vessels, which is believed to be a stem cell niche. The expression of integrin α3 was correlated with migration and invasion. The invasion activity of glioma cells was linked to the phosphorylation of extracellular signal-regulated kinase (ERK) 1/2. CONCLUSION: Our results suggest that integrin α3 contributes to the invasive nature of GSCs via ERK1/2, which renders integrin α3 a prime candidate for anti-invasion therapy for GBM.


Subject(s)
Brain Neoplasms/pathology , Glioma/pathology , Integrin alpha3/genetics , Integrin alpha3/physiology , Neoplastic Stem Cells/metabolism , Brain Neoplasms/genetics , Cell Adhesion/genetics , Cell Movement/genetics , Extracellular Signal-Regulated MAP Kinases/metabolism , Fibronectins/metabolism , Gene Expression Regulation, Neoplastic , Glioma/genetics , Humans , Integrin alpha3/metabolism , MAP Kinase Signaling System/physiology , Neoplasm Invasiveness , Neoplastic Stem Cells/pathology , Phosphorylation , Tumor Cells, Cultured , Up-Regulation/genetics
3.
Xenobiotica ; 35(6): 549-60, 2005 Jun.
Article in English | MEDLINE | ID: mdl-16192107

ABSTRACT

Mexiletine, an anti-arrhythmic agent, is used for the control of ventricular arrhythmias and for neuropathic pain from cancer or diabetes mellitus. It is sometimes used together with psychotropic drugs in patients with depression, schizophrenia or sleep disorder. It is metabolized mainly by cytochrome P450 (CYP) 2 D 6 and, to a minor extent, by CYP1A2. To predict possible drug interactions between mexiletine and psychotropic drugs, the inhibitory effects of 14 psychotropic drugs (phenytoin, carbamazepine, fluvoxamine, paroxetine, fluoxetine, citalopram, sertraline, imipramine, desipramine, haloperidol, thioridazine, olanzapine, etizolam, and quazepam) on mexiletine metabolism in human liver microsomes were determined. Fluoxetine (Ki=0.6+/- 0.1 microM), sertraline (Ki=7.6+/- 0.8 microM) and desipramine (Ki=3.2+/- 0.5 microM) competitively inhibited the mexiletine p-hydroxylation in human liver microsomes. Thioridazine (Kis=0.5+/- 0.2 microM; Kii =3.6+/-1.6 microM) and paroxetine (Kis=1.7+/- 0.7 microM; Kii=3.6+/- 0.9 microM) exhibited a mixed-type inhibition (competitive and non-competitive) toward mexiletine p-hydroxylation in human liver microsomes. The changes of the in vivo clearance of mexiletine by the psychotropic drugs were predicted by 1+(I/Ki) using the in vitro Ki and unbound inhibitor concentrations in liver. The values were calculated as 2.4 for paroxetine, 5.5 for fluoxetine, 1.1 for sertraline, 2.8 for desipramine and 2.2 for thioridazine. In addition, paroxetine exhibited a mechanism-based inactivation with Ki=0.7 microM and Kinact=0.15 min(-1). The present study predicted the possibility of drug interactions between mexiletine and paroxetine, fluoxetine, desipramine, and thioridazine in clinical use.


Subject(s)
Anti-Arrhythmia Agents/metabolism , Mexiletine/metabolism , Microsomes, Liver/drug effects , Microsomes, Liver/metabolism , Psychotropic Drugs/metabolism , Anti-Arrhythmia Agents/pharmacokinetics , Cytochrome P-450 CYP2D6/metabolism , Cytochrome P-450 CYP2D6 Inhibitors , Drug Interactions , Enzyme Activation/drug effects , Humans , Hydroxylation , Metabolic Clearance Rate , Mexiletine/pharmacokinetics , Predictive Value of Tests , Psychotropic Drugs/pharmacokinetics
4.
J Thromb Haemost ; 3(5): 1050-5, 2005 May.
Article in English | MEDLINE | ID: mdl-15869603

ABSTRACT

We examined the role of nitric oxide (NO) produced by an inducible isoform of NO synthase (iNOS) using N[6]-(iminoethyl)-lysine (L-NIL), a selective iNOS inhibitor, in the rat model of lipopolysaccharide (LPS)-induced disseminated intravascular coagulation (DIC) and investigated changes in organ function, plasma levels of NOX (metabolites of NO) and endothelin. We induced experimental DIC by the sustained infusion of 30 mg kg(-1) LPS for 4 h via the tail vein. We then investigated the effect of L-NIL (6 mg kg(-1), from - 0.5 to 4 h) on LPS-induced DIC. Blood was withdrawn at 4 and 8 h, and all four groups (LPS with or without L-NIL at 4 and 8 h) consisted of eight rats. Three of the animals in the 8-h LPS group died, and we examined blood samples from five rats in this group. None of the other rats died. The LPS-induced elevation of creatinine, alanine aminotransferase, glomerular fibrin deposition and plasminogen activator inhibitor was significantly suppressed by L-NIL coadministration, although L-NIL did not affect the platelet count, fibrinogen concentration or the level of thrombin-antithrombin complex. Moreover, plasma levels of the D-dimer that reflect the lysis of cross-linked fibrin were significantly increased by L-NIL coadministration in the LPS-induced DIC model. Plasma levels of NOX and endothelin were obviously increased by LPS infusion. However, both levels were significantly suppressed in the LPS + L-NIL group, when compared with the LPS group. Although mean arterial pressure (MAP) was significantly decreased between 2 and 8 h compared with the control in the LPS group, this depression was significantly attenuated in the LPS + L-NIL group. Our results suggest that NO induced by iNOS contributes to hypotension (depressed MAP), the progression of hepatic and renal dysfunction, microthrombus deposition and elevated endothelin levels in the rat model of LPS-induced DIC.


Subject(s)
Endothelins/biosynthesis , Enzyme Inhibitors/pharmacology , Lysine/analogs & derivatives , Nitric Oxide Synthase/antagonists & inhibitors , Alanine Transaminase/biosynthesis , Animals , Arteries/pathology , Blood Pressure , Creatinine/metabolism , Disseminated Intravascular Coagulation/drug therapy , Endothelins/metabolism , Endothelium, Vascular/metabolism , Fibrin/biosynthesis , Fibrin Fibrinogen Degradation Products/metabolism , Fibrinogen/metabolism , Kidney/metabolism , Lipopolysaccharides/metabolism , Liver/metabolism , Lysine/pharmacology , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II , Plasminogen Activator Inhibitor 1/biosynthesis , Pressure , Rats , Rats, Wistar , Time Factors
5.
Blood Coagul Fibrinolysis ; 13(3): 233-9, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11943937

ABSTRACT

We examined whether JTV-803, a specific activated factor X inhibitor independent of antithrombin III (ATIII), is effective against disseminated intravascular coagulation (DIC) in rat models induced by tissue factor (TF) or lipopolysaccharides (LPS). In male Wistar rats, DIC was induced by a 4 h infusion of thromboplastin (3.75 U/kg) or LPS (50 mg/kg). The rats were given JTV-803 (0.3 or 3 mg/kg, bolus intravenously) (JTV-803 groups) or low molecular weight heparin (LMWH groups) (200 U/kg, bolus intravenously) prior to an injection of TF or LPS. The results showed that JTV-803 was dose-dependently effective against DIC in both TF-induced and LPS-induced rat models. This anti-DIC effect of JTV-803 at higher doses was almost equivalent to that of LMWH in both types of DIC. Plasma ATIII activity was more prominent in the group treated with JTV-803 than in that treated with LMWH. None of rats died in the TF-induced DIC model with or without drug administration. On the contrary, seven of 22 rats died (mortality rate, 31.8%) in the LPS-induced DIC model without drug administration. Although the mortality rate of rats induced with LPS and treated with LMWH was quite high (6/16, 37.5%), none of the LPS-induced rats treated with JTV-803 died. These findings suggested that JTV-803 can treat both TF-induced and LPS-induced DIC models, and that this drug has greater potential in preserving ATIII and in improving the prognosis of DIC.


Subject(s)
Disseminated Intravascular Coagulation/drug therapy , Factor X/antagonists & inhibitors , Isoquinolines/therapeutic use , Lipopolysaccharides/toxicity , Piperidines/therapeutic use , Pyridines/therapeutic use , Tetrahydroisoquinolines , Thromboplastin/toxicity , Animals , Anticoagulants/therapeutic use , Antithrombin III/analysis , Biomarkers , Blood Proteins/analysis , Dalteparin/therapeutic use , Disseminated Intravascular Coagulation/blood , Disseminated Intravascular Coagulation/chemically induced , Disseminated Intravascular Coagulation/pathology , Dose-Response Relationship, Drug , Drug Design , Drug Evaluation, Preclinical , Hemostasis/drug effects , Isoquinolines/administration & dosage , Isoquinolines/pharmacology , Kidney Glomerulus/pathology , Male , Piperidines/administration & dosage , Piperidines/pharmacology , Pyridines/administration & dosage , Pyridines/pharmacology , Rats , Rats, Wistar
6.
J Bone Miner Metab ; 19(5): 287-95, 2001.
Article in English | MEDLINE | ID: mdl-11498730

ABSTRACT

McCune-Albright syndrome (MAS) is sometimes complicated by hypophosphatemia. However, it remains unclear whether a humoral factor is associated with the cause of hypophosphatemia. We isolated cells with mutations of the Gsalpha gene from fibrous bone dysplasia tissues of two MAS patients (MAS cells). Severe combined immunodeficiency (SCID) mice were subjected to experiments using from one of these cells patients. Effects of conditioned media (CM) isolated from MAS cells (MAS-CM) on phosphate transport were investigated by using rat renal slices, the renal cell line OK-B, rat intestinal rings and the human intestinal cell line Caco-2. In addition, the effects of MAS-CM on human sodium-dependent phosphate transporter (NPT2) gene promoter activity expression were investigated in the renal cell line OK-B2400 and were compared with the effects of CM isolated from a patient with oncogenic hypophosphatemic osteomalacia (OHO). MAS cells caused significant hypophosphatemia (P < 0.05) and elevated serum alkaline phosphatase activity (P < 0.05) in SCID mice. The MAS-CM significantly inhibited phosphate uptake in everted intestinal rings (P < 0.01), whereas it had no effect on glucose uptake. The MAS-CM had no effect on either phosphate uptake in the kidney or NPT2 gene promoter activity. In contrast, the CM of the OHO patient significantly inhibited phosphate uptake and NPT2 gene promoter activity. These results indicate that the humoral factor derived from fibrous dysplasia cells of the MAS patient is different to that from OHO patients, because the humoral factor from the MAS patient inhibited phosphate transport not in the kidney but in the intestine.


Subject(s)
Fibrous Dysplasia, Polyostotic/complications , Hypophosphatemia, Familial/etiology , Hypophosphatemia/etiology , Adolescent , Adult , Animals , Bacterial Proteins/genetics , Bacterial Proteins/metabolism , Cells, Cultured , Culture Media, Conditioned/pharmacology , Female , Fibrous Dysplasia, Polyostotic/metabolism , GTP-Binding Protein alpha Subunits, Gs/genetics , Hot Temperature , Humans , Hypophosphatemia/metabolism , Hypophosphatemia, Familial/metabolism , In Vitro Techniques , Jejunum/drug effects , Jejunum/metabolism , Kidney/cytology , Kidney/drug effects , Kidney/metabolism , Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Mice , Mice, SCID , Phosphates/metabolism , Promoter Regions, Genetic , Rats , Rats, Wistar
7.
Kidney Int ; 60(2): 412-5, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11473618

ABSTRACT

Dietary phosphate (Pi) is an important regulator for renal Pi reabsorption. The type II sodium-dependent phosphate (Na/Pi) cotransporters (NPT2) are located at the apical membranes of renal proximal tubular cells and major functional transporters associated with renal Pi reabsorption. The yeast one-hybrid system was used to clone a transcription factor that binds to a specific sequence (Pi response element) in the promoter of the NPT2 gene. Two cDNA clones that encoded protein of the mouse transcription factor mu E3 (TFE3) were isolated. TFE3 may participate in the transcriptional regulation of the NPT2 gene by dietary Pi.


Subject(s)
Carrier Proteins/genetics , Kidney/physiology , Phosphates/metabolism , Phosphorus, Dietary/metabolism , Symporters , Transcription, Genetic/physiology , Animals , Carrier Proteins/metabolism , Humans , Sodium-Phosphate Cotransporter Proteins , Sodium-Phosphate Cotransporter Proteins, Type I , Sodium-Phosphate Cotransporter Proteins, Type II , Sodium-Phosphate Cotransporter Proteins, Type III
8.
J Bone Miner Res ; 16(7): 1256-64, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11450701

ABSTRACT

The major physiological activity of 1,25-dihydroxyvitamin D3 [1,25(OH)2D3] is the regulation of calcium absorption in the small intestine, and the level of vitamin D receptor (VDR) is an important factor in this regulation. In a previous study, we indicated-that the caudal-related homeodomain Cdx-2 played an important role in the intestine-specific transcription of the human VDR gene. In this study, the polymorphism was identified in the core sequence 5'-ATAAAAACTTAT-3' in the Cdx-2 binding site in the VDR gene promoter. In 261 Japanese women with genotyped VDR polymorphisms, 48 were genotype Cdx-A (adenine at -3731 nucleotides [nt] relative to the transcription start site of human VDR gene 5-ATAAAAACTTAT), 82 were genotype Cdx-G (guanine at -3731 nt, 5'-GTAAAAACTTAT-3'), and 131 were genotype Cdx-A/G (heterozygote). In postmenopausal Japanese women, the bone mineral density (BMD) in the lumbar spine (L2-L4) with the Cdx-G homozygote was 12% lower than that with the Cdx-A homozygote (p < 0.05). In electrophoretic gel mobility shift assay (EMSA), the oligonucleotide with Cdx-G allele markedly decreased the binding to Cdx-2 compared with that in the Cdx-A allele. The transcriptional activity of the VDR promoter with Cdx-G allele was decreased to 70% of the Cdx-A allele. In addition, in the herpes simplex virus thymidine kinase promoter, the Cdx-2 binding element with the G allele showed significantly lower transcriptional activity than that of the A allele. Thus, the polymorphism in the Cdx-2 binding site of the VDR gene (Cdx-polymorphism) would affect the expression of VDR in the small intestine. In addition, this polymorphism may modulate BMD in postmenopausal Japanese women.


Subject(s)
Homeodomain Proteins/metabolism , Polymorphism, Genetic/genetics , Receptors, Calcitriol/genetics , Response Elements/genetics , Adult , Aged , Alleles , Animals , Base Sequence , Binding Sites , Bone Density/genetics , CDX2 Transcription Factor , COS Cells , Electrophoretic Mobility Shift Assay , Female , Gene Expression Regulation , Genotype , Homeodomain Proteins/genetics , Humans , Japan , Menopause , Middle Aged , Osteoporosis, Postmenopausal/genetics , Promoter Regions, Genetic/genetics , Spine/physiology , Trans-Activators , Transfection , Tumor Cells, Cultured
9.
Blood Coagul Fibrinolysis ; 12(4): 275-81, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11460011

ABSTRACT

We have attempted to determine whether depressed plasma plasminogen and alpha2 plasmin inhibitor (or alpha2 antiplasmin) activity is, as a result of consumption coagulopathy, a specific finding of disseminated intravascular coagulation (DIC) in septic patients. The hemostatic parameters of 139 septic patients (68 with DIC and 71 without DIC) were analyzed. Among the group as a whole, plasma activities of plasminogen and alpha2 plasmin inhibitor were significantly depressed in septic patients with DIC relative to those without DIC (P < 0.01 and P < 0.05, respectively). Notably, a significant correlation was observed between plasma levels of albumin and plasminogen activity, as well as between plasma levels of albumin and alpha2 plasmin inhibitor activity both in septic patients with DIC and those without DIC. However, no significant correlation was observed between plasma levels of plasmin-alpha2 plasmin inhibitor complex (PIC) and plasminogen activity, nor between PIC and alpha2 plasmin inhibitor activity either in septic patients with DIC or those without DIC. We concluded that depressed activity of plasminogen or alpha2 plasmin inhibitor is not as a result of consumption coagulopathy, but rather a result of low synthetic function of the liver in septic patients with DIC.


Subject(s)
Disseminated Intravascular Coagulation/blood , Plasminogen/metabolism , Sepsis/blood , alpha-2-Antiplasmin/metabolism , Aged , Aged, 80 and over , Blood Coagulation , Disseminated Intravascular Coagulation/physiopathology , Female , Humans , Male , Middle Aged , Sepsis/physiopathology
10.
Blood Coagul Fibrinolysis ; 12(4): 301-6, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11460014

ABSTRACT

All-trans retinoic acid (ATRA) has been introduced to the management of acute promyelocytic leukemia (APL) as a differentiation treatment. This drug not only causes complete remission, but also improves disseminated intravascular coagulation (DIC) without adding anticoagulants in APL. We have attempted to determine whether ATRA is effective against DIC in rat models induced by tissue factor (TF) or lipopolysaccharide (LPS), because the anticoagulant effect of ATRA has been considered to induce thrombomodulin upregulation and TF downregulation on endothelial cells as well as on APL cells. In male Wistar rats, DIC was induced by a 4-h infusion of thromboplastin (3.75 U/kg) or lipopolysaccharide (30 mg/kg). The rats were given ATRA orally each day at a dose of 100 mg/kg per day for 1 week before the injection of TF or LPS in ATRA treatment groups, or given low molecular weight heparin (LMWH) 10 min before the injection of TF or LPS (200 U/kg, bolus intravenously) in LMWH treatment groups. No significant changes in hemostatic parameters or markers of organ dysfunction were caused by the ATRA administration, while DIC was significantly improved by LMWH in the TF-induced model. DIC was significantly improved by both ATRA and LMWH in the LPS-induced model. These findings suggested that ATRA was useful for treating DIC only in the LPS-induced model, and that drug efficacy should be carefully assessed because the agents used to induce DIC considerably influenced the outcome.


Subject(s)
Disseminated Intravascular Coagulation/drug therapy , Keratolytic Agents/therapeutic use , Tretinoin/therapeutic use , Animals , Disease Models, Animal , Disseminated Intravascular Coagulation/chemically induced , Keratolytic Agents/pharmacology , Lipopolysaccharides/toxicity , Male , Rats , Rats, Wistar , Thromboplastin/toxicity , Tretinoin/pharmacology
11.
J Biol Chem ; 276(27): 25558-67, 2001 Jul 06.
Article in English | MEDLINE | ID: mdl-11350959

ABSTRACT

In this study, we investigated the mechanism by which UVB irradiation activates Akt (also known as protein kinase B (PKB)) in mouse epidermal JB6 cells. Treatment with a phosphatidylinositol 3-kinase inhibitor, LY 294002, or expression of a dominant negative mutant of p85 (regulatory component of phosphatidylinositol 3-kinase) inhibited UVB-induced Akt activation. Interestingly, Akt activation by UVB was attenuated by treatment with PD 98059, a specific mitogen-activated protein kinase/extracellular signal-regulated protein kinase (Erk) kinase 1 inhibitor, or SB 202190, a specific p38 kinase inhibitor. Furthermore, the expression of a dominant negative mutant of Erk2 or p38 kinase, but not that of c-Jun N-terminal kinase 1 (JNK1), blocked UVB-induced Akt activation. The expression of a dominant negative mutant of p85 or treatment with LY 294002 also inhibited UVB-induced Erk phosphorylation. The UVB-activated mitogen-activated protein kinase members, which were immunoprecipitated from cells exposed to UVB, did not phosphorylate Akt. Instead, Akt was phosphorylated at both threonine 308 and serine 473 and activated by UVB-activated mitogen- and stress-activated protein kinase 1 (Msk1). The expression of a Msk1 C-terminal kinase-dead mutant inhibited UVB-induced phosphorylation and activation of Akt. These data thus suggested that UVB-induced Akt activation was mediated through Msk1, which is a downstream kinase of the Erk and p38 kinase signaling pathways.


Subject(s)
Calcium-Calmodulin-Dependent Protein Kinases/metabolism , Protein Serine-Threonine Kinases , Proto-Oncogene Proteins/radiation effects , Ribosomal Protein S6 Kinases, 90-kDa , Ultraviolet Rays , Animals , Cell Line , Chromones/pharmacology , Enzyme Activation , Enzyme Inhibitors/pharmacology , Flavonoids/pharmacology , Imidazoles/pharmacology , Insulin/pharmacology , Mice , Mitogen-Activated Protein Kinase 1/genetics , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 8 , Mitogen-Activated Protein Kinases/metabolism , Morpholines/pharmacology , Mutation , Phosphorylation , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , Pyridines/pharmacology , p38 Mitogen-Activated Protein Kinases
12.
J Pharm Pharmacol ; 53(4): 527-33, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11341370

ABSTRACT

We pharmacokinetically examined the effect of gamma-butyrobetaine, a precursor of L-carnitine, on the change of fatty acid metabolism in juvenile visceral steatosis (JVS) mice, which have systemic L-carnitine deficiency due to lack of L-carnitine transporter activity. The concentrations of total free fatty acid (FFA), palmitic acid and stearic acid in the liver of JVS mice were significantly higher than those in wild-type mice. After intravenous administration of gamma-butyrobetaine (50 mg kg(-1)), the concentration of L-carnitine in the plasma of JVS mice reached about twice that of the control level and levels in the brain, liver and kidney were also significantly increased, whereas those in wild-type mice hardly changed. Although the plasma concentrations of FFA in both types of mice were unchanged after administration of gamma-butyrobetaine, the concentrations of palmitic acid and stearic acid were significantly decreased. In particular, the liver concentration of FFA in JVS mice was decreased to the wild-type control level, accompanied by significant decreases in long-chain fatty acids, palmitic acid and stearic acid, whereas those in wild-type mice were not changed. These results suggest that gamma-butyrobetaine can be taken up into organs, including the liver, of JVS mice, and transformed to L-carnitine. Consequently, administration of gamma-butyrobetaine may be more useful than that of L-carnitine itself for treatment of primary deficiency of carnitine due to a functional defect of the carnitine transporter.


Subject(s)
Betaine/analogs & derivatives , Betaine/pharmacology , Carnitine/deficiency , Carrier Proteins/pharmacology , Fatty Acids/metabolism , Liver/chemistry , Organic Cation Transport Proteins , Animals , Betaine/metabolism , Carrier Proteins/drug effects , Disease Models, Animal , Infusions, Intravenous , Liver/physiology , Mice , Solute Carrier Family 22 Member 5
13.
Am J Physiol Regul Integr Comp Physiol ; 279(4): R1230-8, 2000 Oct.
Article in English | MEDLINE | ID: mdl-11003988

ABSTRACT

To evaluate the influences of gamma-aminobutyric acid (GABA) mechanisms on bladder hyperactivity after left middle cerebral artery occlusion, cystometric recordings were obtained from unanesthetized female rats. Intracerebroventricular administration of both muscimol (GABA(A) receptor agonist; 0.1-10 nmol) and baclofen (GABA(B) receptor agonist; 0.1-3 nmol) produced dose-dependent inhibitions of micturition with increases in bladder capacity (BC). The effects of high doses (1-10 nmol) were similar in sham-operated (SO) and cerebral-infarcted (CI) rats. However, lower doses of muscimol (0.1 or 0.3 nmol) and baclofen (0.1 nmol) reduced BC in CI rats. After bicuculline (GABA(A) receptor antagonist; 1 or 3 nmol) administration, BC in both SO and CI rats first decreased and subsequently increased. An increase in urethral pressure was observed after administration of bicuculline (3 nmol) but not with either muscimol or baclofen. Infarct volumes in muscimol-, bicuculline-, or baclofen-treated rats were not significantly different from those of vehicle-treated rats. These results suggest that GABAergic mechanisms inhibit the micturition reflex at the supraspinal level but that this can change as a result of CI.


Subject(s)
Baclofen/pharmacology , Cerebral Infarction/physiopathology , Cerebral Ventricles/physiology , Middle Cerebral Artery/physiology , Muscimol/pharmacology , Urinary Bladder/physiology , Animals , Baclofen/administration & dosage , Bicuculline/administration & dosage , Bicuculline/pharmacology , Cerebral Ventricles/drug effects , Cerebral Ventricles/physiopathology , Dose-Response Relationship, Drug , Female , GABA-A Receptor Agonists , GABA-B Receptor Agonists , Injections, Intraventricular , Muscimol/administration & dosage , Pressure , Rats , Rats, Sprague-Dawley , Seizures/physiopathology , Urinary Bladder/drug effects , Urinary Bladder/physiopathology , Urination/drug effects , Urination/physiology
14.
Jpn J Pharmacol ; 83(2): 135-42, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10928326

ABSTRACT

To clarify the mechanism of the benefical effect of Choto-san on cerebral circulation in hypertensive patients, the influence of Choto-san on cerebral blood flow (CBF) during hemorrhagic hypotension was evaluated in 10- to 11-month-old spontaneously hypertensive rats. The lower limit of CBF autoregulation, defined as the mean arterial blood pressure at which CBF decreased by 10% of the baseline value, was dose-dependently lowered when Choto-san (0.5 - 2.0 g/kg per day, p.o.) was administered for 14 consecutive days. Uncariae Ramulus et Uncus (150 mg/kg per day, p.o.), one of the crude drug components of Choto-san, showed an effect equivalent to that of Choto-san. The action of Choto-san (2.0 g/kg per day, p.o.) or Uncariae Ramulus et Uncus on the autoregulatory response of cerebral vessels was eliminated by treatment with N(G)-nitro-L-arginine methyl ester (10 mg/kg, i.v.), an inhibitor of nitric oxide synthase. These results suggested that the activation of nitric oxide synthase by Uncariae Ramulus et Uncus contributed to at least part of the improvement in the cerebral circulation caused by Choto-san.


Subject(s)
Cerebrovascular Circulation/drug effects , Drugs, Chinese Herbal/pharmacology , Animals , Blood Pressure/drug effects , Male , NG-Nitroarginine Methyl Ester/pharmacology , Nitroprusside/pharmacology , Rats , Rats, Inbred SHR , Rats, Inbred WKY
15.
Clin Exp Pharmacol Physiol ; 27(8): 587-93, 2000 Aug.
Article in English | MEDLINE | ID: mdl-10901387

ABSTRACT

1. The combined effects of the macrolide antibiotics erythromycin, josamycin, clarithromycin and YM17K (3,4'-dideoxy mycaminosyl tylonolide hydrochloride) on in vitro intracellular accumulation of vinblastine or cyclosporine (Cs)A and on the in vivo antitumour activity of vinblastine were investigated using mouse leukaemia P388 cells (P388/S) and anticancer drug-resistant (P388/ADR) cells. These effects were compared with those of a calcium antagonist (verapamil) or immunosuppressants (FK506 and CsA). 2. All tested macrolide antibiotics increased the accumulation of both vinblastine and CsA in P388/ADR cells in a dose-dependent manner, but their potency was lower than that of verapamil, CsA or FK506. 3. When vinblastine (200 microg/kg) was administered intraperitoneally with each of the macrolide antibiotics (10 or 100 mg/kg) or with verapamil (25 mg/kg) once a day for 10 days in P388/ADR-bearing mice, combined effects of vinblastine with the macrolide antibiotics (erythromycin, clarithromycin and YM17K) or verapamil were observed. 4. The present study suggests that macrolide antibiotics may overcome anticancer drug resistance by inhibiting the binding of vinblastine or CsA to P-glycoprotein in P388/ADR cells. 5. We believe that these results are encouraging for combination chemotherapy to overcome P-glycoprotein-dependent anticancer drug-resistant tumours in clinical practice.


Subject(s)
Anti-Bacterial Agents/pharmacology , Antineoplastic Agents/pharmacology , Drug Resistance, Neoplasm , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Animals , Antineoplastic Agents/metabolism , Antineoplastic Agents, Phytogenic/metabolism , Antineoplastic Agents, Phytogenic/pharmacology , Calcium Channel Blockers/pharmacology , Cell Membrane/drug effects , Cell Membrane/metabolism , Cell Survival/drug effects , Cyclosporine/pharmacology , Immunosuppressive Agents/pharmacology , Leukemia P388/metabolism , Macrolides , Mice , Neoplasm Transplantation , Tumor Cells, Cultured , Verapamil/pharmacology , Vinblastine/metabolism , Vinblastine/pharmacology
16.
Biochem Biophys Res Commun ; 270(1): 254-9, 2000 Apr 02.
Article in English | MEDLINE | ID: mdl-10733936

ABSTRACT

Organic anions are secreted into urine via organic anion transporters across the renal basolateral and apical membranes. However, no apical membrane transporter for organic anions such as p-aminohippuric acid (PAH) has yet been identified. In the present study, we showed that human NPT1, which is present in renal apical membrane, mediates the transport of PAH. The K(m) value for PAH uptake was 2.66 mM and the uptake was chloride ion sensitive. These results are compatible with those reported for the classical organic anion transport system at the renal apical membrane. PAH transport was inhibited by various anionic compounds. Human NPT1 also accepted uric acid, benzylpenicillin, faropenem, and estradiol-17beta-glucuronide as substrates. Considering its chloride ion sensitivity, Npt1 is expected to function for secretion of PAH from renal proximal tubular cells. This is the first molecular demonstration of an organic anion transport function for PAH at the renal apical membrane.


Subject(s)
Carrier Proteins/metabolism , Cell Polarity , Kidney/metabolism , Symporters , p-Aminohippuric Acid/metabolism , Anions/metabolism , Biological Transport/drug effects , Carrier Proteins/genetics , Humans , Phosphates/metabolism , Recombinant Proteins/metabolism , Sodium-Phosphate Cotransporter Proteins , Sodium-Phosphate Cotransporter Proteins, Type I , Sodium-Phosphate Cotransporter Proteins, Type III
17.
J Clin Endocrinol Metab ; 85(3): 1215-9, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10720065

ABSTRACT

To determine the influence of estrogen on the activity of renal proximal tubular reabsorption of inorganic phosphate (Pi) in women, we examined the changes of the renal threshold phosphate concentration (also denoted as TmP/GFR), as well as the changes in the concentrations of mineral components in the circulation in two groups of women--one receiving hormone replacement therapy (HRT) and one receiving gonadotropin-releasing hormone agonists (GnRH-a) therapy. We also examined the changes in the concentrations of serum PTH in the GnRH-a group. The patients in the HRT group were continuously treated with 0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate per day. The patients in the GnRH-a group were treated with a monthly injection of 3.75 mg leuprolide acetate depot for 6 months. The values of TmP/GFR decreased in all of the patients who received HRT. The mean percentage change in TmP/GFR was -14.5% (range, -24.3% to -9.6%). In contrast, in all of the patients treated with GnRH-a, the values of TmP/GFR increased after 6 months of treatment (the mean percentage change was 28.5%; range, 18.2-78.3%) and returned to the preadministration level at 12 weeks after stopping therapy. In these patients, both the values of TmP/GFR and the concentrations of serum Pi correlated significantly with circulating estradiol levels (r = -0.767, P < 0.01 and r = -0.797, P < 0.01, respectively), but the concentrations of serum corrected calcium did not correlate. Moreover, in the same patients, the levels of serum intact PTH decreased significantly (P < 0.05) after 6 months of treatment, but at 12 weeks after stopping therapy the trends of these levels varied among individual patients. These results suggest that estrogen could act directly to suppress sodium-dependent Pi reabsorption in the renal proximal tubules.


Subject(s)
Estrogen Replacement Therapy , Kidney/metabolism , Phosphates/metabolism , Adult , Bone Density , Climacteric/metabolism , Endometriosis/drug therapy , Endometriosis/metabolism , Estradiol/blood , Female , Glomerular Filtration Rate , Gonadotropin-Releasing Hormone/agonists , Humans , Hysterectomy , Middle Aged , Parathyroid Hormone/blood
18.
Nutrition ; 15(10): 749-54, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10501287

ABSTRACT

The daily pattern of energy expenditure and the oxidation rates of carbohydrates, fats, and protein were evaluated by indirect calorimetry in 18 control subjects (Group 1) and 34 cirrhotic patients who were divided into Groups 2a and 2b showing indocyanin green retention rates at 15 min of <30% and 30% or more, respectively. The ratio of resting energy expenditure to basal energy expenditure (%REE) was higher in the cirrhotic patients than in the controls at 8:30 AM and 2:30 PM. The oxidation rates of carbohydrates and fats under fasting conditions in Group 2b patients were respectively lower, and higher than in Group 1 and 2a patients. After the subjects ate, glucose became the substrate preferentially metabolized, and the proportion of fat metabolized was reduced from 82.9+/-5.1% to 43.9+/-21.9% and from 70.7+/-14.1% to 46.8+/-13.9% in the patients with advanced and less advanced cirrhosis, respectively, and from 59.4+/-27.2% to 48.4+/-18.5% in the controls. The fasting concentrations of non-esterified fatty acids in Group 2b were also significantly higher than those in the Group 1 and Group 2a patients. After eating, these concentrations fell and reached similar levels in the patients and controls. These data indicated that the patients with cirrhosis developed the catabolic state of starvation in the morning because of a lack of glycogen stores. Therefore, frequent meal supplementation to prevent early-onset starvation and energy deficiency may be advisable in such patients to maintain a well-nourished condition.


Subject(s)
Energy Metabolism , Liver Cirrhosis/metabolism , Aged , Basal Metabolism , Calorimetry, Indirect , Dietary Carbohydrates/metabolism , Dietary Fats/metabolism , Dietary Proteins/metabolism , Fasting , Fatty Acids, Nonesterified/blood , Food , Glycogen/metabolism , Humans , Middle Aged , Oxidation-Reduction
19.
J Biol Chem ; 273(37): 23629-32, 1998 Sep 11.
Article in English | MEDLINE | ID: mdl-9726963

ABSTRACT

A cDNA was isolated from rat C6 glioma cells by expression cloning which encodes a novel Na+-independent neutral amino acid transporter designated LAT1. For functional expression in Xenopus oocytes, LAT1 required the heavy chain of 4F2 cell surface antigen (CD98), a type II membrane glycoprotein. When co-expressed with 4F2 heavy chain, LAT1 transported neutral amino acids with branched or aromatic side chains and did not accept basic amino acids or acidic amino acids. The transport via LAT1 was Na+-independent and sensitive to a system L-specific inhibitor 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid. These functional properties correspond to those of the classically characterized amino acid transport system L, a major nutrient transporter. In in vitro translation, LAT1 was shown to be a nonglycosylated membrane protein consistent with the property of 4F2 light chain, suggesting LAT1 is at least one of the proteins formerly referred to as 4F2 light chain. LAT1 exhibits relatively low but significant amino acid sequence similarity to mammalian cationic amino acid transporters and amino acid permeases of bacteria and yeasts, indicating LAT1 is a new member of the APC superfamily. Because of highly regulated nature and high level of expression in tumor cell lines, LAT1 is thought to be up-regulated to support the high protein synthesis for cell growth and cell activation. The cloning of LAT1 is expected to facilitate the research on the protein-protein interaction in the transporter field and to provide a clue to the search for still unidentified transporters.


Subject(s)
Amino Acids, Cyclic , Amino Acids/metabolism , Antigens, CD/metabolism , Carrier Proteins/metabolism , Amino Acid Sequence , Amino Acid Transport Systems , Amino Acids/pharmacology , Animals , Antigens, CD/chemistry , Antigens, CD/genetics , Biological Transport/drug effects , Carrier Proteins/chemistry , Carrier Proteins/genetics , Cloning, Molecular , Female , Fusion Regulatory Protein-1 , Glioma , Macromolecular Substances , Male , Microsomes/metabolism , Molecular Sequence Data , Oocytes/physiology , Organ Specificity , Protein Biosynthesis , Rats , Recombinant Proteins/biosynthesis , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Substrate Specificity , Tumor Cells, Cultured , Xenopus laevis
20.
Biochem J ; 333 ( Pt 1): 175-81, 1998 Jul 01.
Article in English | MEDLINE | ID: mdl-9639577

ABSTRACT

Dietary Pi and parathyroid hormone (PTH) are two most important physiological and pathophysiological regulators of Pi re-absorption in the renal proximal tubule. Effects of dietary Pi on Na+/Pi co-transporter NaPi-2 were investigated in thyroparathyroidectomized (TPTX) rats. NaPi-2 protein and mRNA in the kidney cortex of TPTX rats were increased approximately 3.8- and 2.4-fold in amount respectively compared with those in the sham-operated animals. Administration of PTH to the TPTX rats resulted in a decrease in the amount of NaPi-2 protein, but not in the abundance of NaPi-2 mRNA. Deprivation of dietary Pi in the TPTX rats did not affect the amount of NaPi-2 mRNA and protein. In the Pi-deprived TPTX rats, feeding of a high-Pi diet resulted in marked decreases in Pi transport activity and the amount of NaPi-2 protein in the superficial nephrons. Immunohistochemical analysis demonstrated that administration of PTH to TPTX rats resulted in a decrease in NaPi-2 immunoreactivity from both superficial and juxtamedullary nephrons within 4 h. Switching TPTX animals from a low-Pi diet to the high-Pi diet decreased NaPi-2 immunoreactivity from superficial nephrons, but not from juxtamedullary nephrons, within 4 h. These results suggest that dietary Pi could regulate the amount of NaPi-2 protein in the superficial nephrons in a PTH-independent manner.


Subject(s)
Carrier Proteins/metabolism , Kidney/drug effects , Phosphates/pharmacology , Phosphorus, Dietary/pharmacology , Symporters , Animals , Biological Transport/drug effects , Carrier Proteins/biosynthesis , Endocytosis/physiology , Immunoblotting , Kidney/metabolism , Kidney/ultrastructure , Kidney Cortex/drug effects , Kidney Cortex/metabolism , Kidney Cortex/ultrastructure , Male , Microvilli/drug effects , Microvilli/metabolism , Nephrons/drug effects , Nephrons/metabolism , Parathyroid Hormone/metabolism , Parathyroid Hormone/pharmacology , Parathyroidectomy , Phosphates/administration & dosage , Phosphorus, Dietary/administration & dosage , RNA, Messenger/biosynthesis , Rats , Rats, Sprague-Dawley , Sodium-Phosphate Cotransporter Proteins , Thyroidectomy
SELECTION OF CITATIONS
SEARCH DETAIL
...